文献速递泌尿男性生殖肿瘤

立体定向放疗在转移性肾细胞癌治疗策略中的研究:Getug协作组

Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group.
PubMed 文献 · Eur J Cancer · 2018-06-01

全组6、12、24个月局部控制率分别为87.5%、82.9%、77.6%,中位无进展生存8.5个月、总生存29.2个月,严重毒性发生率2.6%。结论认为SRT对寡转移和寡进展患者有效且安全,可能延迟系统治疗的启动或更换。

要点

  • SRT对转移性肾细胞癌的局部控制率较高,24个月达77.6%。
  • 全组中位总生存29.2个月,严重毒性发生率仅2.6%。
  • SRT可能延迟寡转移/寡进展患者系统治疗的启动或更换。

核心结论

  • SRT对寡转移和寡进展性肾细胞癌患者有效且安全,可能延迟系统治疗的引入或更换。

研究设计与样本

  • 回顾性研究,收集2008至2015年六家法国转诊中心接受根治性意图SRT的全部肾细胞癌患者数据。

主要发现

  • 全组6、12、24个月局部控制率分别为87.5%、82.9%、77.6%。
  • 全组中位无进展生存期8.5个月,中位局部无复发生存期23.2个月,中位至系统治疗时间13.2个月,中位总生存期29.2个月。
  • 寡进展患者(101例)中位无进展生存、至系统治疗时间、总生存分别为8.6、10.5、23.2个月;寡转移患者(80例)分别为7.6、14.2、33.9个月。
  • 对系统治疗部分缓解后接受SRT的7例患者中,3例在中位随访22个月时未复发。
  • 急性和晚期严重毒性见于5例(2.6%)患者。

临床怎么用

  • 对于寡转移或寡进展性转移性肾细胞癌,SRT可作为局部治疗选择以延长无进展生存并延迟系统治疗启动或更换。
  • SRT严重毒性发生率低,在筛选患者时可考虑其安全性。

局限性

  • 回顾性研究设计,可能存在选择偏倚。
  • 样本来自六家法国转诊中心,外推性需谨慎。
  • 部分亚组(如系统治疗后部分缓解者仅7例)样本量小,结论有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Renal cell carcinoma (RCC) is usually considered radioresistant, but stereotactic radiation therapy (SRT) may increase local disease control. This study aimed to assess the benefit of SRT in the management of metastatic RCC patients. METHODS: Data of all RCC patients who received SRT between 2008 and 2015 with curative intent were retrospectively collected in six French referral centres. Local control (LC), progression-free survival (PFS), local recurrence-free survival (LRFS), time to systemic therapy (TTS) and overall survival (OS) were assessed. RESULTS: One hundred and eighty-eight patients treated with SRT for 252 RCC metastases (brain [n = 120]; spine [n = 75]; and others [n = 57]) were recensed. SRT was performed for oligoprogressive disease (101 patients), oligometastatic disease (80 patients) or residual tumour after a partial response to systemic treatment (7 patients). The median biologically effective dose was 78 Gy. For the whole population, local control rates at 6, 12 and 24 months were 87.5%, 82.9% and 77.6%, respectively; median PFS, LRFS, TTS and OS were 8.5, 23.2, 13.2 and 29.2 months, respectively. Among patients treated for oligoprogressive/oligometastatic disease, the median PFS, TTS, and OS were 8.6/7.6, 10.5/14.2 and 23.2/33.9 months, respectively. Among the 7 patients treated with SRT after partial response to systemic treatment, no relapse occurred for 3 of them after a median follow-up of 22 months. Acute and late severe toxicities were noted in 5 (2.6%) patients. CONCLUSIONS: SRT is effective and safe for oligometastatic and oligoprogressive RCC patients and may delay introduction or change of systemic therapy.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Meyer E, Pasquier D, Bernadou G, et al. Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group. Eur J Cancer. 2018. PMID: 29864737. doi:10.1016/j.ejca.2018.04.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。